Details for Patent: 12,357,630

« Back to Dashboard

Which drugs does patent 12,357,630 protect, and when does it expire?

Patent 12,357,630 protects ZYKADIA and is included in one NDA.

This patent has thirty-five patent family members in twenty-six countries.

Summary for Patent: 12,357,630

Title:	Ceritinib formulation
Abstract:	The present disclosure relates to a new pharmaceutical composition comprising Ceritinib. Particularly it is directed to the tablet that is prepared by wet granulation, wherein povidone is used as a binder. Further feature of the composition is that the drug and the binder form the inner phase, whereas all other excipients are added in a powder form as an outer phase. This way, the sticking of the composition is prevented and sufficient tablet hardness can be reached.
Inventor(s):	Sebastien Breulles, Simon ENSSLIN
Assignee:	Novartis AG
Application Number:	US17/168,265
Patent Claim Types: see list of patent claims	Use; Composition; Formulation; Dosage form;

Drugs Protected by US Patent 12,357,630

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Novartis	ZYKADIA	ceritinib	TABLET;ORAL	211225-001	Mar 18, 2019		RX	Yes	Yes	12,357,630					TREATMENT OF ADULT PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHOSE TUMORS ARE ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE AS DETECTED BY AN FDA-APPROVED TEST

International Family Members for US Patent 12,357,630

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	100625
Australia	2015265470
Australia	2018203007
Australia	2019232937